An observational study in Rhinitis Allergic, Persistent, sponsored by UCB Pharma. Completed at 1 site in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2012-05-28.
Sponsored by UCB Pharma · Observational
To evaluate over a period of 6 months the safety and the treatment satisfaction of newly prescribed levocetirizine in patients of age ≥ 2 years with persistent allergic rhinitis.
This is a non-interventional, prospective, post-authorization, multi-centre cohort study in patients treated with levocetirizine.
The baseline data will be collected at the visit to the physician when levocetirizine is prescribed for the first time for the patient for Persistent Allergic Rhinitis. The data will then be collected during 2 visits occurring within the first 6 months of treatment, as usually scheduled in normal clinical practice in the Czech and Slovak Republics. This is after approximately 4 weeks and 6 months of treatment or earlier, if the treatment is stopped
1,105 studies on the registry are indexed under Rhinitis; 65 are open to participants now.
This study's enrollment of 7,870 is above the median of 141 across 172 observational studies indexed under Rhinitis.
Browse Rhinitis studies →UCB Pharma is the lead sponsor of 238 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with newly diagnosed persistent allergic rhinitis, within the approved age limits.
Age ≥ 2 years
Exclusion Criteria:
Patients with newly diagnosed persistent allergic rhinitis, within the approved age limits.
Number of patients with adverse events Number and type of serious adverse events Number of patients withdrawing levocetirizine treatment due to adverse events
Time frame: Six Months
To evaluate the global clinical improvement on levocetirizine compared to baseline at each follow up visit.
Time frame: Six months
To evaluate the treating physician's perception of patient satisfaction of levocetirizine tolerability at each follow up visit
Time frame: six months
To evaluate symptoms (nasal pruritus, rhinorrhea, nasal congestion, sneezing, ocular pruritus) at each follow up visit
Time frame: six months
To evaluate the impact of co-morbidities (asthma, urticaria and inflammation of upper airways) at each follow up visit
Time frame: six months
To evaluate the treating physician's perception of patient satisfaction of treatment regimen effectiveness at each follow up visit
Time frame: six months
To evaluate the treating physician's prescription practice in the treatment of Persistent Allergic Rhinitis
Time frame: six months
To evaluate concomitant medications prescribed with levocetirizine at each follow up visit
Time frame: six months
The evaluate reason for discontinuation at last follow up visit
Time frame: six months
To evaluate the overall physician´s treatment satisfaction in comparison with previously used antihistamines in patient population previously treated by antihistamines at last follow up visit
Time frame: six months
To evaluate the dose prescribed by the treating physician at each follow up visit
Time frame: six months
This study is completed, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
UCB Pharma